Over the past 12 months, 15 insiders at ANI PHARMACEUTICALS INC filed 60 open-market SEC Form 4 transactions on ANIP: 0 purchases worth $0 and 60 sales worth $49.7M. Insiders have been net sellers over this period. The most recent filing was on Jul 13, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $81.84 | $41K |
| Jul 2, 26 | Stephen P. CareySVP & CFO | SELL | 3.3K | $86.00 | $285K |
| Jun 29, 26 | Stephen P. CareySVP & CFO | SELL | 2.9K | $84.12 | $240K |
| Jun 12, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $82.03 | $41K |
| Jun 8, 26 | Thomas Haughey | SELL | 2.0K | $80.88 | $162K |
| Jun 5, 26 | Stephen P. CareySVP & CFO | SELL | 3.3K | $80.00 | $265K |
| May 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $78.16 | $39K |
| May 13, 26 | Patrick D Walsh | SELL | 10.0K | $80.63 | $806K |
| May 12, 26 | Ori GutwergSVP, GENERICS | SELL | 2.8K | $79.50 | $220K |
| May 12, 26 | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | SELL | 459 | $79.21 | $36K |
| May 11, 26 | Nikhil LalwaniPRESIDENT & CEO | SELL | 55.0K | $77.57 | $4.3M |
| May 11, 26 | Patrick D Walsh | SELL | 4.0K | $80.75 | $321K |
| Apr 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $77.95 | $39K |
| Mar 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $72.62 | $36K |
| Mar 13, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 3.2K | $71.64 | $227K |
| Mar 11, 26 | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | SELL | 4.8K | $74.91 | $357K |
| Mar 9, 26 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 5.1K | $74.13 | $377K |
| Mar 9, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 3.6K | $74.18 | $267K |
| Mar 6, 26 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 1.5K | $75.00 | $111K |
| Mar 6, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 2.1K | $74.22 | $157K |
| Mar 5, 26 | Stephen P. CareySVP & CFO | SELL | 4.0K | $75.56 | $302K |
| Mar 3, 26 | Ori GutwergSVP, GENERICS | SELL | 2.1K | $76.50 | $158K |
| Mar 3, 26 | Patrick D WalshDirector | SELL | 6.0K | $74.23 | $445K |
| Mar 2, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 417 | $74.00 | $31K |
| Feb 20, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 5.3K | $78.02 | $415K |
| Feb 20, 26 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 1.7K | $77.99 | $135K |
| Feb 19, 26 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 2.1K | $77.53 | $162K |
| Feb 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $76.80 | $38K |
| Feb 12, 26 | Christopher MutzHEAD OF RARE DISEASE | SELL | 7.0K | $76.55 | $538K |
| Jan 13, 26 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $84.33 | $42K |
| Dec 18, 25 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 1.6K | $82.40 | $134K |
| Dec 12, 25 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 400 | $82.32 | $33K |
| Dec 5, 25 | Renee P TannenbaumDirector | SELL | 1.8K | $81.15 | $146K |
| Nov 13, 25 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 400 | $87.27 | $35K |
| Nov 13, 25 | Patrick D WalshDirector | SELL | 8.6K | $86.88 | $751K |
| Nov 13, 25 | Chad GassertSVP - CORP. DEV. & STRATEGY | SELL | 94 | $88.00 | $8K |
| Nov 12, 25 | Chad GassertSVP - CORP. DEV. & STRATEGY | SELL | 14.6K | $89.07 | $1.3M |
| Oct 13, 25 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 400 | $90.09 | $36K |
| Sep 19, 25 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 1.0K | $98.04 | $98K |
| Sep 12, 25 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | SELL | 400 | $98.42 | $39K |
| Sep 3, 25 | Antonio R PeraDirector | SELL | 7.3K | $94.94 | $692K |
| Aug 25, 25 | Matthew J LeonardDirector | SELL | 2.5K | $90.62 | $229K |
| Aug 22, 25 | Krista DavisSVP, CHIEF HR OFFICER | SELL | 1.8K | $91.10 | $161K |
| Aug 21, 25 | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS | SELL | 53.0K | $90.44 | $4.8M |
| Aug 20, 25 | Antonio R PeraDirector | SELL | 5.4K | $89.73 | $486K |
| Aug 20, 25 | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS | SELL | 47.0K | $90.27 | $4.2M |
| Aug 18, 25 | Matthew J LeonardDirector | SELL | 6.9K | $88.17 | $612K |
| Aug 18, 25 | Jeanne ThomaDirector | SELL | 14.7K | $89.76 | $1.3M |
| Aug 15, 25 | Chad GassertSVP - CORP. DEV. & STRATEGY | SELL | 20.0K | $86.97 | $1.7M |
| Aug 15, 25 | Patrick D WalshDirector | SELL | 9.0K | $89.05 | $801K |
Over the past 12 months, insiders at ANI PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 60 sales worth $49.7M on ANIP, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 13, 26.
15 different insiders at ANI PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on ANIP over the last 12 months.
InsiderTape plots every ANIP insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every ANI PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →